driver mutation nsclc: combining targeted and i-o therapy
Published 5 years ago • 72 plays • Length 3:21Download video MP4
Download video MP3
Similar videos
-
3:30
trials of i-o therapy in driver mutation nsclc
-
6:00
considering use of i-o therapy in driver mutation nsclc
-
6:08
considering use of i-o therapy in driver mutation nsclc
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
5:29
the role of driver mutations in nsclc treatment - 2022 program: lcvl
-
3:48
i-o as first-line therapy for driver-mutated nsclc
-
2:20
selecting patients with nsclc who benefit from immunotherapy or targeted therapies
-
4:09
impact of driver mutations in nsclc
-
3:44
what is a driver mutation?
-
8:14
approaching non-driver stage iv nsclc
-
6:04
the future of driver mutations in nsclc
-
5:47
impower150: combining vegf and i-o therapy in nsclc
-
16:35
heterogeneity of nsclc and precipitating oncogenic driver mutations
-
6:00
immunotherapy for patients with driver mutation - lung cancer video library
-
4:23
evolution of targeted therapy in advanced nsclc
-
3:04
final thoughts on targeted therapy and i/o agents in nsclc
-
4:08
role for immunotherapy for patients with driver mutations
-
5:59
targeted therapy in consolidation setting for lung cancer
-
3:33
molecular drivers and therapeutic targets for neuroendocrine transformation in lung cancer